Medicare Part D transition supplies: first fills and pharmacy steps

A Part D transition supply gives an enrollee temporary access to an otherwise non-formulary drug while the patient and prescriber move to a covered alternative or request an exception. It is an access bridge, not a permanent formulary override. A claim may qualify when a drug is absent from the plan formulary, when a prior authorization or step-therapy edit applies, or when the plan’s quantity limit is below the patient’s current dose. CMS’s Part D Benefits Manual explains that the policy is designed to protect ongoing drug therapy from an avoidable interruption. The actual claim still must be a Part D drug and meet the plan’s processing rules.

Which situations can trigger a transition fill?

The transition policy can apply when a person joins a new Part D plan, changes plans during the year, becomes newly eligible, or faces a negative formulary change at the start of a contract year. It may also matter when an existing enrollee experiences an unplanned change in level of care, such as leaving a hospital for a long-term care facility. A member does not have to wait for an annual enrollment date: CMS describes the transition period as beginning with the effective date of the relevant enrollment. A patient who moves into a plan partway through the year may therefore still have a transition period tied to that individual enrollment date.

A non-formulary drug for transition purposes is broader than a drug missing from the printed formulary. CMS includes drugs that require prior authorization or step therapy when the enrollee has not met the plan’s requirement, as well as a formulary drug whose approved quantity limit is lower than the patient’s current dose. A prior exception that expires can also leave ongoing treatment subject to transition rules. A plan may still apply safety-related edits and determine whether a drug is covered under Part D at all. Transition status does not convert an excluded drug into a Part D benefit or eliminate clinical safeguards.

The first-fill workflow at the pharmacy

When a claim rejects, first read the exact message and identify whether the issue is non-formulary status, prior authorization, step therapy, quantity limit, eligibility, or another coverage rule. Confirm the patient’s plan and effective date, then ask whether this is a new enrollment or a change in coverage. Follow the pharmacy’s payer-specific transition billing workflow or contact the plan’s pharmacy help desk if the claim response is unclear. Do not assume that every rejection qualifies, and do not change the drug, strength, directions, or quantity without the required pharmacist and prescriber authorization.

If the plan approves a temporary fill, explain plainly that it is temporary and that the patient should contact the prescriber and plan promptly. The follow-up may be a switch to a therapeutically appropriate formulary alternative, completion of prior authorization, or a formulary exception request. A transition fill is not proof that the plan will cover all future refills at the same cost. The pharmacy can provide the plan’s contact information, document what happened, and route clinical questions to the pharmacist. Avoid promising approval or suggesting that the patient simply wait until the supply runs out.

Retail and long-term care supplies are different

CMS’s manual describes a 90-day transition window after coverage begins. In a retail setting, the temporary supply must generally provide at least 30 days of medication unless the prescriber wrote for fewer than 30 days. Multiple fills may be needed to reach the minimum. In long-term care, CMS describes a longer transition supply—at least 91 days, potentially up to 98 days to accommodate dispensing increments—unless the prescription is for a shorter period. LTC residents outside the transition window may also be entitled to a separate emergency supply while a coverage request is pending. These are distinct rules, so do not apply a retail day-supply assumption to an LTC claim.

The transition window is measured from the enrollee’s effective date, not simply from January 1 or the start of a plan year. A transition fill can occur at any point during the initial 90 days if needed. If a person leaves and later reenrolls with a gap, a new period may begin; a continuous enrollment without a coverage gap generally does not create a fresh window. The plan may also have a transition extension process when an exception or appeal is still unresolved at the end of the minimum period. Pharmacy staff should not calculate a guaranteed number of refills from the calendar alone; use the plan response and current CMS policy.

What the temporary fill does not do

Transition processing is not the same as a formulary exception, a prior authorization approval, or a clinical decision that a medicine is appropriate. It does not permanently add the product to the plan formulary, waive every utilization rule, or authorize a technician to recommend a therapeutic substitution. The patient may still owe the applicable cost sharing. A plan can continue safety edits, verify Part A, Part B, or Part D coverage, and reject drugs that are not covered under Part D. An exception request is the path for asking the plan to continue coverage under an applicable rule; the plan sponsor—not the pharmacy—makes that decision.

Example: a new plan rejects an established medicine

A patient begins a new Part D plan in February and brings an established maintenance prescription to a network pharmacy. The claim rejects because prior authorization is required. Staff verify the plan effective date and the rejection details, then use the plan’s transition process rather than treating the rejection as an ordinary refill denial. If a temporary supply is approved, the pharmacy tells the patient that the fill is short-term and asks them to contact the prescriber about the plan’s authorization criteria or a covered alternative. The pharmacist reviews urgency and any clinical concerns. The team documents the claim response and next steps; it does not promise that the same prescription will pay next month.

PTCB exam takeaways

For the PTCE, remember the purpose first: continuity during a coverage transition. Recognize that non-formulary transition cases include certain prior-authorization, step-therapy, and quantity-limit barriers. Know that the 90-day period begins with the enrollee’s effective coverage date and that retail and LTC supply amounts differ. A temporary claim payment is not permanent approval. In a workplace scenario, identify the rejection, follow the payer’s process, inform the patient that action is needed before the bridge ends, document the interaction, and refer clinical or exception decisions to the pharmacist, prescriber, and plan.

How to verify a transition claim

Use the current Part D plan’s transition policy and real-time claim response for the operational instructions. The CMS manual provides the federal baseline and describes timing, supply, notice, and special-setting rules; the plan implements its approved process. If a response is ambiguous, ask the plan whether it is a transition rejection or a standard coverage edit and what submission code or override is required. Recheck the current policy when rules change. This is particularly important for dates, days’ supply, network status, and level-of-care transitions, which can affect the appropriate pathway.